DUBLIN, September 8, 2021 / PRNewswire / – The report “Pharmaceutical Contract Manufacturing Market, 2030” has been added to ResearchAndMarkets.com offer.
The Pharmaceutical Contract Manufacturing Market report (3rd Edition) presents an in-depth study of the current market landscape and future opportunities associated with the Pharmaceutical Contract Manufacturing industry.
One of the main objectives of the report was to understand the major growth drivers and estimate future opportunities in the market based on several parameters such as the growth of the overall pharmaceutical market, cost of goods sold, cost of direct manufacturing. We have provided an informed estimate of the likely evolution of the market in the short, medium and long term, for the period 2021-2030.
Today, the pharmaceutical industry is dominated by the presence of small molecule products, which account for nearly 80% of the overall pipeline. Although biologics have shown great promise in treating a wide range of disorders, in recent years the approval of new small molecules has increased. In fact, as of 2020, more than 50 small molecule drugs have been approved by the US FDA, while approximately 8,000 of these candidates are under evaluation at various stages of development.
It should be mentioned that the pipeline presents increasingly complex candidates, which require specialized facilities, advanced equipment and operational expertise. Since building / acquiring manufacturing capabilities is both a time consuming and expensive process, it is extremely difficult for pharmaceutical companies to conduct development and manufacturing operations independently.
The aforementioned constraints, coupled with the growing demand for safer and more effective drugs (currently driven by the COVID-19 pandemic), have prompted players to outsource a significant portion of their business segments to manufacturing organizations under contract (CMO), as well as contract development and manufacturing. organizations (CDMO).
The current landscape of contracted pharmacy service providers is highly fragmented, with a mix of start-ups, mid-sized companies and established players. The inherent expertise of CMOs and CDMOs is believed to be able to reduce the time to market of a product, achieve significant cost-benefits, as well as access to larger production capacities and new technologies.
It should be mentioned that there has been significant M&A activity in the pharmaceutical contract manufacturing market in recent years as players strive to become one-stop shops, to meet the diverse needs of pharmaceutical developers (ranging from early stage development to commercial production).
Considering the continuous innovation in production technologies, the evolution of the pipeline of small molecule products and the growing demand for such drug candidates, we believe that the pharmaceutical contract manufacturing market is expected to experience a positive growth in the years to come.
Answers to key questions
- Who are the main players involved in providing small molecule contract manufacturing services?
- What are the main value drivers of M&A activity seen in the contract pharmaceutical industry?
- What are the various expansion initiatives undertaken by pharmaceutical contract manufacturers in the recent past?
- Which regions represent the main current contract manufacturing centers for small molecules? What is the current installed capacity for contract manufacturing of small molecules?
- What is the current global demand for small molecules? How is the demand for such candidates likely to evolve in the foreseeable future?
- What percentage of pharmaceutical manufacturing operations are currently outsourced?
- What factors should be taken into consideration in deciding whether small molecule manufacturing operations should be kept in-house or outsourced?
- How is the current and future opportunity likely to be distributed among key market segments?
Main topics covered:
2. Executive summary
4. Regulatory Landscape for Contract Pharmaceutical Manufacturers
5. Pharmaceutical CMOs: current market landscape
6. Regional capacity
7. Company profiles
8. Make versus Buy decision framework
9. Mergers and acquisitions
10. Recent extensions
11. Capacity analysis
12. Analysis of the request
13. Market forecast
14. Key information
15. SWOT analysis
16. Case Study: Comparison of Small and Large Molecule Drugs / Therapies
17. Final remarks
18. Perspectives of the executive
19. Annex I: Tabulated data
20. Annex II: List of companies and organizations
For more information on this report, visit https://www.researchandmarkets.com/r/tfg1je
Research and markets
Laura Wood, senior
For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets